QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lam, J. Y Articles by Cates, M. E Search for Related Content PubMed PubMed Citation Articles by Lam, J. Y Articles by Cates, M. E

PSYCHIATRY

Modafinil Augmentation for Residual Symptoms of Fatigue in Patients with a Partial Response to Antidepressants

Pharmacy Practice Resident, University of Alabama Health System—Birmingham, Birmingham, AL

Maisha Kelly Freeman, PharmD BCPS

Assistant Professor of Pharmacy Practice, Drug Information Specialist, McWhorter School of Pharmacy, Samford University, Birmingham, AL

Marshall E Cates, PharmD BCPP FASHP

Professor of Pharmacy Practice, McWhorter School of Pharmacy, Samford University

Reprints: Dr. Freeman, McWhorter School of Pharmacy, Samford University, 800 Lakeshore Dr., Birmingham, AL 35229, fax 205/726-4012, mkelly{at}samford.edu

OBJECTIVE: To evaluate the literature discussing the use of modafinil in the treatment of residual symptoms of fatigue in patients with depression.

DATA SOURCES: PubMed (1966-March 2007) and International Pharmaceutical Abstracts (1970-March 2007) were searched using the key words modafinil and depression. A manual search of the reference section of the articles retrieved was conducted to identify articles not indexed in either of these sources.

STUDY SELECTION AND DATA EXTRACTION: All articles published in English were evaluated. Studies were included if modafinil was used to treat patients with residual fatigue from depression and the effects were measured with validated fatigue subscales.

DATA SYNTHESIS: One retrospective study, 5 open-label trials, and 2 randomized controlled clinical trials met the inclusion criteria for assessment of residual symptoms of fatigue as assessed by commonly used fatigue subscales after modafinil administration. Although improvement with fatigue has occurred with modafinil therapy, literature regarding the topic is limited by the lack of well-controlled clinical trials. Modafinil does appear to improve residual fatigue with depression as evidenced by open-label trials; however, the efficacy of this agent has not been duplicated in randomized controlled trials. The open-label trials that have been conducted often had no comparator and a small number of patients. In addition, outcome measures used in the studies were not consistent between trials. Modafinil appears to be well tolerated, with the main adverse effects being headache and nausea.

CONCLUSIONS: Open-label trials indicate that modafinil may be effective in ameliorating fatigue associated with depression; however, this effect has not been reproduced in randomized, double-blind, placebo-controlled clinical trials. Therefore, the use of modafinil for the treatment of residual fatigue is not recommended due to the lack of reproducible data of its efficacy. Long-term, adequately powered clinical trials should be conducted to determine its place in therapy.

Key Words: antidepressants, depression, modafinil

Published Online, May 22, 2007. www.theannals.com, DOI 10.1345/aph.1H526

This article has been cited by other articles:

				B. Ng and A. O'Brien Beyond ADHD and narcolepsy: psychostimulants in general psychiatry Adv. Psychiatr. Treat., July 1, 2009; 15(4): 297 - 305. [Abstract] [Full Text] [PDF]

				P Hagell and L Brundin Towards an understanding of fatigue in Parkinson disease J. Neurol. Neurosurg. Psychiatry, May 1, 2009; 80(5): 489 - 492. [Abstract] [Full Text] [PDF]